PeptideStack
5.2kquestions
20kanswers
220users

Why did two FGP lots of cagrilintide differ on content assay?

Asked 15 Mar 2025Modified 12 months agoViewed 39k times
37

Stated plainly: FGP · cagrilintide.

This is not behaving the way I expected and I want to understand the discrepancy before I act on it.

I have photographed the current state and recorded the conditions, so I can answer follow-up questions precisely.

Is this recoverable, and how would I tell?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

438 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

436 questions
shareeditfollowflag
VF
askedvial_five15k2815 Mar 2025
3For what it is worth, my own result was within half a per cent of this. – ben_akintola 5 months ago
4Any reason this would differ for a longer peptide? – tess_amankwah 7 months ago
add a comment

5 Answers

Sorted by votes
81

The single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Mass shifts and what they usually mean

Δ mass (Da)Most likely causeDistinguishing feature
+1Deamidation (Asn or Gln)New peak, slightly earlier retention
−17Loss of ammoniaOften with deamidation
−18Dehydration / succinimidepH-dependent, reversible
+16Oxidation (Met, Trp)Earlier retention, light-related
−128Missing Gln or LysDeletion sequence from synthesis
0Isomer: racemisation or scramblingSame mass, shifted retention

Specifically, if the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 29 Jul 2025 by b_delacroix — updated for the 2026 guidance change

shareimprove this answerflag
BD
answeredb_delacroix48k387 Jul 2025
3This should probably be in the site help pages rather than buried in an answer. – linnea_wahlberg 6 months ago
4Good answer, but the confidence interval in the cited trial is wider than implied. – nine_point_nine 8 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
53

Thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
AN
answeredamara_nwachukwu41k3820 Mar 2025
3Good answer, but the confidence interval in the cited trial is wider than implied. – h_pergande 6 months ago
add a comment
42

A certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.

The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

Specifically, a statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
NT
answeredn_takahashi36k3831 Mar 2025
34

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
TG
answeredtandem_gradient85k24811 Apr 2025
26

More usefully, batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
DV
answeredDr_Bram_Verhoeven85k24822 Apr 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.